The ROE as of November 2024 (TTM) for Olema Pharmaceuticals, Inc. (OLMA) is -53.55%

According to Olema Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -53.55%. This represents a change of 293.81% compared to the average of -13.60% of the last 4 quarters.

Olema Pharmaceuticals, Inc. (OLMA) Historical ROE (quarterly & annually)

How has OLMA ROE performed in the past?

The mean historical ROE of Olema Pharmaceuticals, Inc. over the last ten years is -7.65%. The current -53.55% ROE has changed 599.98% with respect to the historical average. Over the past ten years (40 quarters), OLMA's ROE was at its highest in in the March 2020 quarter at 135.87%. The ROE was at its lowest in in the September 2024 quarter at -17.37%.

Olema Pharmaceuticals, Inc. (OLMA) ROE by Quarter and Year

Discovering the peaks and valleys of Olema Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Olema Pharmaceuticals, Inc. (OLMA) Average ROE

How has OLMA ROE performed in the past?

The current ROE of Olema Pharmaceuticals, Inc. (OLMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Olema Pharmaceuticals, Inc. (OLMA) ROE vs. Peers

How is OLMA’s ROE compared to its peers?

Olema Pharmaceuticals, Inc.’s ROE is greater than Sana Biotechnology, Inc. (-94.47%), greater than Cullinan Oncology, Inc. (-26.54%), greater than aTyr Pharma, Inc. (-56.83%), greater than Zentalis Pharmaceuticals, Inc. (-43.92%), greater than Molecular Partners AG (-39.16%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than Pharvaris N.V. (-38.27%), greater than PepGen Inc. (-60.17%), greater than Gracell Biotechnologies Inc. (-15.56%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Design Therapeutics, Inc. (-18.01%), greater than Erasca, Inc. (-42.26%), greater than Disc Medicine, Inc. (-25.24%), greater than Larimar Therapeutics, Inc. (-35.87%), less than Fennec Pharmaceuticals Inc. (31.99%), greater than Orchestra BioMed Holdings, Inc. (-107.04%), greater than Nuvectis Pharma, Inc. (-155.80%), greater than Centessa Pharmaceuticals plc (-52.22%),

Build a custom stock screener for Olema Pharmaceuticals, Inc. (OLMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Olema Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Olema Pharmaceuticals, Inc. (OLMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Olema Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.